HAM
ANIP icon

Highstreet Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Highstreet Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Hold
22
– – ﹤0.01% 621
2019
Q3 		$2K Buy
+22
New +$1.65K ﹤0.01% 349

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Highstreet Asset Management's ANIP Position: Q4 2019 in Review

Highstreet Asset Management held its ANI Pharmaceuticals (ANIP) position steady in Q4 2019 at 22 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #621.

Highstreet Asset Management first reported a position in ANIP in Q3 2019 and has held it in 2 quarters since. The position peaked at $2K in Q3 2019. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

  • Highstreet Asset Management held 22 shares of ANI Pharmaceuticals worth $1K as of Q4 2019.
  • Highstreet Asset Management left its ANI Pharmaceuticals share count unchanged in Q4 2019.
  • ANI Pharmaceuticals made up ﹤0.01% of Highstreet Asset Management's portfolio in Q4 2019, its #621 holding.
  • Highstreet Asset Management first reported a position in ANI Pharmaceuticals in Q3 2019 and has held it in 2 quarters since.
  • Highstreet Asset Management's ANI Pharmaceuticals position peaked at $2K in Q3 2019.
  • 170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Highstreet Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.